Chimeric Therapeutics Ltd (ASX:CHM) Share Price

Company Profile

Business description
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
Contact
62 Lygon Street
Level 3, Carlton
MelbourneVIC3053
AUS
T: +61 398245254
https://www.chimerictherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,061.20	61.30	-0.67%
CAC 40	7,853.59	1.02	-0.01%
DAX 40	23,639.41	35.12	-0.15%
Dow JONES (US)	46,315.27	172.85	0.37%
FTSE 100	9,216.67	11.44	-0.12%
HKSE	26,545.10	106.59	0.40%
NASDAQ	22,631.48	160.75	0.72%
Nikkei 225	45,045.81	143.54	0.32%
NZX 50 Index	13,231.66	3.23	-0.02%
S&P 500	6,664.36	32.40	0.49%
S&P/ASX 200	8,773.50	75.00	-0.85%
SSE Composite Index	3,820.09	11.57	-0.30%